A closer look at Aptevo's November financing shows up to $15 million in additional potential proceeds, as the company highlights mipletamig data ahead of a 2027 FDA meeting.
The company initiated two new oncology studies in October and November and said a first-line zipalertinib NDA submission is expected to complete in November.
An NDA submission under the FDA's Real-Time Oncology Review program began October 1, 2026, backed by Phase 3 REZILIENT3 progression-free survival data.